Deal History

Advised on acquisition of Smart Immune (cell therapy/ProTcell platform) by MeiraGTx Holdings. Acquisition strengthened MeiraGTx's RiboCAR platform for gene therapy.

Advised on merger of GRI Bio (NKT cell regulatory platform) with Vallon Pharmaceuticals, combining clinical-stage therapeutic pipelines.

Advised on $16M private placement financing for GRI Bio prior to Vallon merger.

Advised on acquisition of Alethia Biopharmaceuticals (cancer immunotherapy) by NantBioscience, a strategic healthcare platform.

Advised through multi-year engagement. Supported bridge financings (Dec 2020, Jan 2021), Series A $20M (Apr 2021), and ultimate merger with Seneca Biopharma resulting in Palisade Bio (Nasdaq: PALI). Company developing LB1148 for post-operative GI dysfunction.

Advised on acquisition of Gotham Therapeutics (RNA-targeted oncology platform) by 858 Therapeutics. 858 formed with $60M Series A to advance oncology program.

Multi-year advisory on VBI Vaccines (viral vector vaccine platform). Supported bridge financing ($1.5M, Mar 2014), secured debt facility ($6M, Jul 2014), and private placements ($16.25M, Jul 2014) culminating in reverse merger with Paulson Capital resulting in public company (Nasdaq: VBIV).

Advised Viveve (women's health technology platform for non-invasive vaginal restoration) on reverse merger with PLC Systems shell. Included $6M private placement financing.

Advised on $41M Series A financing for AI-driven antibody discovery company. Investors: Lumira Ventures (lead), Investissement Québec, Fonds de solidarité FTQ, adMare BioInnovations. Proceeds to advance lead asset (KJ-103, TROP2-targeting antibody) into first-in-human trial with Cancer Research UK partnership.